Trilaciclib clinical trials
Also written G1T28 and Cosela.
How each study uses trilaciclib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trilaciclib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 12 Feb 2021 · COSELA · NDA 214200 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
35 studies that test it; most in 2024 (11)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 1 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 11 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 21
G1 Therapeutics, Inc. (9) · Jiangsu Simcere Pharmaceutical Co., Ltd. (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Sun Yat-sen University (3) · Pharmacosmos A/S (2) · Wake Forest University Health Sciences (1) · Henan Cancer Hospital (1) · Shandong Cancer Hospital and Institute (1)
Often tested with
Tested in the same studies.
Gemcitabine (2) · Cisplatin (2) · Pembrolizumab (1) · Carboplatin (1) · Eribulin (1) · Tislelizumab (1) · Antineoplastic Agents (1) · PM 01183 (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9, 3 in phase 3
Studies that test trilaciclib, phase 3 first.
- Apr 2027A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.Phase 3 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Jul 2027A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung CancerPhase 3 · Jiangsu Simcere Pharmaceutical Co., Ltd.
- Oct 2027Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung CancerPhase 3 · Pharmacosmos A/S
- Dec 2026Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Phase 2 · Sun Yat-sen University
- Dec 2026Study of Trilaciclib and LurbinectidinPhase 2 · UNC Lineberger Comprehensive Cancer Center
- Dec 2026The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBCPhase 2 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Aug 2027Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerPhase 2 · Wake Forest University Health Sciences
- Aug 2027Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid TumorsPhase 1 · Hebei Medical University Fourth Hospital
- Sep 2027Trilaciclib Combined With Immunochemotherapy for R/M HNSCCPhase 2 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Studies
Open first, then newest update. How each study uses trilaciclib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 35
- Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung CancerRecruitingPhase 3Pharmacosmos A/SNCT07473128Written as Trilaciclib
- Study of Trilaciclib and LurbinectidinRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT05578326Written as Trilaciclib
- Trilaciclib Combined With Immunochemotherapy for R/M HNSCCNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07679997Written as Trilaciclib
- Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid TumorsRecruitingPhase 1Hebei Medical University Fourth HospitalNCT07490236Written as Trilaciclib group
- the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With TrilaciclibEnrolling by invitationPhase 2Henan Cancer HospitalNCT06370416Written as Trilaciclib
- Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Not yet recruitingPhase 2Sun Yat-sen UniversityNCT07255612Written as Trilaciclib
- Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLCRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06929936Written as Trilaciclib combined with Docetaxel
- Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBCRecruitingPhase 2QIAO LINCT06955156Written as Trilaciclib
- A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.Not yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06364904Written as Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib
- Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCCRecruitingPhase 2Hunan Cancer HospitalNCT06752798Written as Trilaciclib + Cisplatin
- Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Shandong Cancer Hospital and InstituteNCT06714266Written as Trilaciclib
- Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of OsteosarcomaRecruitingPhase 2Peking University People's HospitalNCT06714383Written as Trilaciclib
- Trilaciclib Prevents Myelosuppression With ChemoradiotherapyRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06490081Written as Trilaciclib
- Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06569459Written as Trilaciclib Injection [Cosela]
- A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma PatientsRecruitingPhase 2Sun Yat-sen UniversityNCT06569485Written as Trilaciclib+R-CHOP
- A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal MetastasisRecruitingPhase 2Jiangsu Province Nanjing Brain HospitalNCT06332287Written as combination of Trilaciclib and Pemetrexed
- A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLCRecruitingPhase 2Taixing People's HospitalNCT06328049Written as Trilaciclib Injection
- Myeloprotection With Trilaciclib in Pan-cancer PopulationNot yet recruitingPhase 2Sun Yat-sen UniversityNCT06297811Written as Trilaciclib Injection
- A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06151262Written as Trilaciclib+mFOLFIRINOX
- Trilaciclib Combined With Chemotherapy for Perioperative Treatment of OsteosarcomaNot yet recruitingPhase 2The First Affiliated Hospital of Xinxiang Medical CollegeNCT06217003Written as Trilaciclib
See all 35 studies that test trilaciclib →
Given beside what is tested · 8 — trilaciclib is usual care or a partner of the new treatment
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Trilaciclib with or without trastuzumab + pertuzumab
- Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06992739Written as Trilaciclib and Sacituzumab Tirumotecan
- Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and CarboplatinRecruitingPhase 2Shanghai Chest HospitalNCT06698965Written as Trilaciclib
- A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using TrilaciclibRecruitingPhase 2Fudan UniversityNCT06699472Written as Trilaciclib Injection [Cosela]
- Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant ChemotherapyRecruitingPhase 2wang shusenNCT05978648Written as Trilaciclib
- Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLCNot yet recruitingPhase 2Fudan UniversityNCT05910034Written as Trilaciclib+Envafolimab+Docetaxel
- Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung CancerNot yet recruitingPhase 2Sichuan UniversityNCT05900921Written as Trilaciclib
- Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)TerminatedPhase 2G1 Therapeutics, Inc.NCT02978716Written as Trilaciclib
What changed recently
From the registry's own updates since Oct 18, 2026.
Codes
What other systems call trilaciclib · ClinicalTrials.gg INT001357
- MeSH (NLM) C000708352trilaciclibOne source NLM
- UNII (FDA) U6072DO9XGTRILACICLIBConfirmed FDA, NLM, Wikidata
- RxNorm 2479690One source FDA
- Wikidata Q105592965trilaciclibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C123281TrilaciclibOne source FDA
- DrugBank DB15442One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000708352 | trilaciclib | One source NLM |
| UNII (FDA) | U6072DO9XG | TRILACICLIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2479690 | — | One source FDA |
| Wikidata | Q105592965 | trilaciclib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C123281 | Trilaciclib | One source FDA |
| DrugBank | DB15442 | — | One source Wikidata |
Also registered as trilaciclib dihydrochloride (UNII 4BX07W725T · RxNorm 2479691).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.